Actavis and Forest Labs have agreed to sell or relinquish their rights to four generic pharmaceuticals to settle antitrust concerns stemming from their planned merger.
via WSJ.com: US Business http://ift.tt/1z3v5UW
via WSJ.com: US Business http://ift.tt/1z3v5UW
Nessun commento:
Posta un commento